Abstract
Enteroviruses such as Coxsackievirus B3 can cause dilated cardiomyopathy, but the mechanism of this pathology is unknown. Mutations in cytoskeletal proteins such as dystrophin cause hereditary dilated cardiomyopathy, but it is unclear if similar mechanisms underlie acquired forms of heart failure. We demonstrate here that purified Coxsackievirus protease 2A cleaves dystrophin in vitro as predicted by computer analysis. Dystrophin is also cleaved during Coxsackievirus infection of cultured myocytes and in infected mouse hearts, leading to impaired dystrophin function. In vivo, dystrophin and the dystrophin-associated glycoproteins α-sarcoglycan and β-dystroglycan are morphologically disrupted in infected myocytes. We suggest a molecular mechanism through which enteroviral infection contributes to the pathogenesis of acquired forms of dilated cardiomyopathy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Schocken, D.D., Arrieta, M.I., Leaverton, P.E. & Ross, E. A. Prevalence and mortality rate of congestive heart failure in the United States. J. Am. Coll. Cardiol. 20, 301– 306 (1992).
Cohn, J.N. et al. Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel on Heart Failure Research. Circulation 95, 766–770 (1997).
Dargie, H.J., McMurray, J.J. & McDonagh, T.A. Heart failure—implications of the true size of the problem. J. Intern. Med. 239, 309 –315 (1996).
Baboonian, C., Davies, M.J., Booth, J.C. & McKenna, W.J. Coxsackie B viruses and human heart disease. Curr. Top. Microbiol. Immunol. 223, 31–52 ( 1997).
Sole, M.J. & Liu, P. Viral myocarditis: a paradigm for understanding the pathogenesis and treatment of dilated cardiomyopathy. J. Am. Coll. Cardiol. 22, 99A–105A (1993).
Leiden, J.M. The genetics of dilated cardiomyopathy–emerging clues to the puzzle. N. Engl. J. Med. 337, 1080– 1081 (1997).
Towbin, J.A. The role of cytoskeletal proteins in cardiomyopathies. Curr. Opin. Cell Biol. 10, 131–139 ( 1998).
Malhotra, S. B. et al. Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy. Science 242, 755– 759 (1988).
Beggs, A.H. Dystrophinopathy, the expanding phenotype. Dystrophin abnormalities in X-linked dilated cardiomyopathy. Circulation 95, 2344–2347 (1997).
Berko, B.A. & Swift, M. X-linked dilated cardiomyopathy. N. Engl. J. Med. 316, 1186–91 (1987).
Towbi, J.A. et al. X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy locus. Circulation 87, 1854–1865 ( 1993).
Muntoni, F. et al. Brief report: Deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. N. Engl. J. Med. 329, 921–5 ( 1993).
Olson, T.M., Michels, V.V., Thibodeau, S.N., Tai, Y. S. & Keating, M.T. Actin mutations in dilated cardiomyopathy, an inheritable form of heart failure. Science 280, 750–752 (1998).
Maeda, M., Holder, E., Lowes, B., Valent, S. & Bies, R.D. Dilated cardiomyopathy associated with deficiency of the cytoskeletal protein metavinculin. Circulation 95, 17–20 (1997).
Fadic, R. et al. Brief report: deficiency of a dystrophin-associated glycoprotein (adhalin) in a patient with muscular dystrophy and cardiomyopathy. N. Engl. J. Med. 334, 362–6 (1996).
Nigro, V. et al. Identification of the Syrian hamster cardiomyopathy gene. Hum. Mol. Genet. 6, 601– 607 (1997).
Grady, R.M. et al. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 90, 729–738 (1997).
Arber, S. et al. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 88, 393–403 (1997).
Wessely, R., Henke, A., Zell, R., Kandolf, R. & Knowlton, K.U. Low level expression of a mutant coxsackieviral cDNA induces a myocytopathic effect in culture: An approach to the study of enteroviral persistence in cardiac myocytes. Circulation 98, 450–457 (1998).
Wessely, R. et al. Transgenic expression of replication-restricted enteroviral genomes in heart muscle induces defective excitation-contraction coupling and dilated cardiomyopathy. J. Clin. Invest. 102, 1444–1453 (1998).
Rueckert, R. R. in Fundamental Virology Vol. 3 (eds. Fields, B.N., Knipe, D.M. & Howley, P.M.) 477–522 (Raven, New York, 1996).
Gradi, A. et al. A novel functional human eukaryotic translation initiation factor 4G. Mol. Cell Biol. 18, 334– 342 (1998).
Lamphear, B.J. et al. Mapping of the cleavage site in protein synthesis initiation factor eIF-4 gamma of the 2A proteases from human Coxsackievirus and rhinovirus. J. Biol. Chem. 268, 19200– 19203 (1993).
Blom, N., Hansen, J., Blaas, D. & Brunak, S. Cleavage site analysis in picornaviral polyproteins: discovering cellular targets by neural networks. Protein Sci. 5, 2203–2216 (1996).
Sheng, Z. et al. Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. Divergence from downstream CT-1 signals for myocardial cell hypertrophy. J. Biol. Chem. 272, 5783–5791 ( 1997).
Setoguchi, M. et al. Expression and localization of dystrophin in cultured neonatal rat cardiac myocytes. Biochem. Biophys. Res. Commun. 194, 1012–1018 (1993).
Ervasti, J.M., Kahl, S.D. & Campbell, K.P. Purification of dystrophin from skeletal muscle. J. Biol. Chem. 266, 9161–9165 (1991).
Chow, L.H., Beisel, K.W. & McManus, B.M. Enteroviral infection of mice with severe combined immunodeficiency. Evidence for direct viral pathogenesis of myocardial injury. Lab. Invest. 66, 24–31 (1992).
Henke, A., Huber, S., Stelzner, A. & Whitton, J.L. The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis. J. Virol. 69, 6720–6728 ( 1995).
Straub, V., Rafael, J.A., Chamberlain, J.S. & Campbell, K.P. Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J. Cell Biol. 139, 375– 385 (1997).
Ervasti, J.M., Ohlendieck, K., Kahl, S.D., Gaver, M. G. & Campbell, K.P. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 345, 315–9 ( 1990).
Straub, V. & Campbell, K.P. Muscular dystrophies and the dystrophin-glycoprotein complex. Curr. Opin. Neurol. 10, 168–175 (1997).
Rybakova, I.N. & Ervasti, J.M. Dystrophin-glycoprotein complex is monomeric and stabilizes actin filaments in vitro through a lateral association. J. Biol. Chem. 272, 28771–28778 (1997).
Roberts, R.G. & Bobrow, M. Dystrophins in vertebrates and invertebrates. Hum. Mol. Genet. 7, 589– 595 (1998).
Koenig, M. & Kunkel, L.M. Detailed analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility. J. Biol. Chem. 265, 4560– 4566 (1990).
Chen, P.H., Ornelles, D.A. & Shenk, T. The adenovirus L3 23-kilodalton proteinase cleaves the amino-terminal head domain from cytokeratin 18 and disrupts the cytokeratin network of HeLa cells. J. Virol. 67, 3507 –3514 (1993).
Shoeman, R.L. et al. Cleavage of human and mouse cytoskeletal and sarcomeric proteins by human immunodeficiency virus type 1 protease. Actin, desmin, myosin, and tropomyosin. Am. J. Pathol. 142, 221– 230 (1993).
Knowlton, K.U., Jeon, E.S., Berkley, N., Wessely, R. & Huber, S. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of CVB3. J. Virol. 70 (11), 7811– 7818 (1996).
Schwimmbeck, P.L., Badorff, C., Schultheiss, H.P. & Strauer, B.E. Transfer of human myocarditis into severe combined immunodeficiency mice. Circ. Res. 75, 156–164 (1994).
Bader, D., Masaki, T. & Fischman, D.A. Immunochemical analysis of myosin heavy chain during avian myogenesis in vivo and in vitro. J. Cell Biol. 95, 763–770 ( 1982).
Nicholson, L.V. et al. Dystrophin in skeletal muscle. I. Western blot analysis using a monoclonal antibody. J. Neurol. Sci. 94, 125–136 (1989).
Morris, G.E. et al. An epitope structure for the C-terminal domain of dystrophin and utrophin. Biochemistry 37, 11117– 11127 (1998).
Spencer, M.J., Walsh, C.M., Dorshkind, K.A., Rodriguez, E.M. & Tidball, J.G. Myonuclear apoptosis in dystrophic mdx muscle occurs by perforin-mediated cytotoxicity. J. Clin. Invest. 99, 2745–2751 ( 1997).
Sommergruber, W. et al. Mutational analyses support a model for the HRV2 2A proteinase. Virology 234, 203–214 (1997).
Schwarz, E.M. et al. NF-kappaB-mediated inhibition of apoptosis is required for encephalomyocarditis virus virulence: a mechanism of resistance in p50 knockout mice. J. Virol. 72, 5654– 5660 (1998).
Acknowledgements
Antibody MF20, developed by D.A. Fishman and colleagues, was obtained from the Developmental Studies Hybridoma Bank maintained by the University of Iowa Department of Biological Sciences (Iowa City, Iowa 52242, USA) under contract NO1-HD-7-3263 from the NICHD. Suang Huang provided assistance with the adenovirus experiments. This work was supported by grant Ba 1668/1-1 from the Deutsche Forschungsgemeinschaft to C.B.; grants from the American Heart Association (96-306A) and UCSD Biotechnology Star Project (S96-38) to K.U.K.; and grant GM20818 from the NIH to R.E.R. K.P.C. is an Investigator of the Howard Hughes Medical Institute.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Badorff, C., Lee, GH., Lamphear, B. et al. Enteroviral protease 2A cleaves dystrophin: Evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 5, 320–326 (1999). https://doi.org/10.1038/6543
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/6543
This article is cited by
-
Letale lymphozytäre Myokarditis – eine unterschätzte Diagnose im Säuglings- und Kindesalter?
Die Pathologie (2023)
-
State-of-the-Art of Endomyocardial Biopsy on Acute Myocarditis and Chronic Inflammatory Cardiomyopathy
Current Cardiology Reports (2022)
-
The absolute and relative changes in high-sensitivity cardiac troponin I are associated with the in-hospital mortality of patients with fulminant myocarditis
BMC Cardiovascular Disorders (2021)
-
Myocarditis and inflammatory cardiomyopathy: current evidence and future directions
Nature Reviews Cardiology (2021)
-
Promising Therapy for Heart Failure in Patients with Severe COVID-19: Calming the Cytokine Storm
Cardiovascular Drugs and Therapy (2021)